Lupin’s wholly owned subsidiary -- Nanomi B.V., the Netherlands (Nanomi) has entered into definitive agreements to acquire the minority shareholding from certain existing shareholders of Multicare Pharmaceuticals Philippines, Inc. (MPPI), a subsidiary of Nanomi. This acquisition involves 11,794,497 shares, which accounts for 43.38% of the total outstanding paid up shares of MPPI. The transaction is expected to be completed by the end of May 2026, subject to certain closing conditions.
The proposed acquisition will strengthen the company’s market standing in the Philippines market (through its wholly owned subsidiary Nanomi) and allow substantial integration of MPPI’s operations. It also allows strategic flexibility, enabling the company to unify emerging-market businesses and unlock long-term value.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: